ROS1 and non-small cell lung carcinoma: In the phase II eligible population, the ORR was 86% among 14 patients with ROS1-rearranged disease (all but one with NSCLC), and an ORR of 57% among seven patients with ALK-rearranged tumors, including NSCLC, renal cell carcinoma, and CRC (Drilon et al. 2017).